{"id":25191,"date":"2025-12-09T12:40:44","date_gmt":"2025-12-09T12:40:44","guid":{"rendered":"https:\/\/itbusinesstoday.com\/?p=25191"},"modified":"2025-12-09T12:40:44","modified_gmt":"2025-12-09T12:40:44","slug":"kura-and-kyowa-report-strong-komzifti-aml-data","status":"publish","type":"post","link":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/kura-and-kyowa-report-strong-komzifti-aml-data\/","title":{"rendered":"\u30af\u30e9\u3068\u5354\u548c\u3001KOMZIFTI AML\u30c7\u30fc\u30bf\u306e\u597d\u8abf\u3092\u5831\u544a"},"content":{"rendered":"

\u30af\u30e9\u30fb\u30aa\u30f3\u30b3\u30ed\u30b8\u30fc\u3068 \u5354\u548c\u30ad\u30ea\u30f3<\/a> KOMZIFTI\u30b8\u30d5\u30c8\u30e1\u30cb\u30d6\u3068\u30d9\u30cd\u30c8\u30af\u30e9\u30c3\u30af\u30b9\u304a\u3088\u3073\u30a2\u30b6\u30b7\u30c1\u30b8\u30f3\u306e\u4f75\u7528\u7642\u6cd5\u306b\u95a2\u3059\u308b\u65b0\u305f\u306a\u30c7\u30fc\u30bf\u3092\u767a\u8868\u3057\u307e\u3057\u305f\u3002NPM1\u907a\u4f1d\u5b50\u5909\u7570\u307e\u305f\u306fKMT2A\u518d\u914d\u5217\u3092\u6709\u3059\u308b\u65b0\u898f\u8a3a\u65ad\u304a\u3088\u3073\u518d\u767a\u30fb\u96e3\u6cbb\u6027AML\u306e\u4e21\u65b9\u3067\u826f\u597d\u306a\u7d50\u679c\u304c\u5f97\u3089\u308c\u307e\u3057\u305f\u3002\u3053\u306e\u7d50\u679c\u306f\u3001\u73fe\u5728\u9032\u884c\u4e2d\u306eKOMET 007\u30d5\u30a7\u30fc\u30ba1a\/1b\u8a66\u9a13\u304b\u3089\u5f97\u3089\u308c\u305f\u3082\u306e\u3067\u3001\u672c\u65e5ASH 2025\u3067\u767a\u8868\u3055\u308c\u307e\u3057\u305f\u3002.<\/p>\n

\u65b0\u305f\u306bNPM1\u5909\u7570AML\u3068\u8a3a\u65ad\u3055\u308c\u305f\u60a3\u8005\u306b\u304a\u3044\u3066\u3001\u30c8\u30ea\u30d7\u30ec\u30c3\u30c8\u306f\u5f37\u529b\u306a\u52b9\u679c\u3092\u793a\u3057\u307e\u3057\u305f\u3002\u8a55\u4fa1\u53ef\u80fd\u306a37\u4eba\u306e\u60a3\u8005\u306e\u3046\u3061\u3001CRc\u306f86\uff05\u3001\u5b8c\u5168\u594f\u52b9\u306f73\uff05\u3067\u3057\u305f\u3002\u6700\u3082\u9855\u8457\u3060\u3063\u305f\u306e\u306f\u3001CRc\u594f\u52b9\u4f8b\u306e68\u30d1\u30fc\u30bb\u30f3\u30c8\u304c\u4e2d\u592eNGS\u306b\u3088\u3063\u3066\u5206\u5b50\u7684MRD\u3092\u30af\u30ea\u30a2\u3057\u305f\u3053\u3068\u3067\u3059\u3002\u594f\u52b9\u671f\u9593\u3068\u5168\u751f\u5b58\u671f\u9593\u306e\u4e2d\u592e\u5024\u306b\u306f\u307e\u3060\u9054\u3057\u3066\u3044\u307e\u305b\u3093\u3002\u30c7\u30fc\u30bf\u30ab\u30c3\u30c8\u30aa\u30d5\u6642\u70b9\u3067\u3001\u60a3\u8005\u306e3\u5206\u306e2\u306f\u307e\u3060\u751f\u5b58\u3057\u3066\u304a\u308a\u3001\u6cbb\u7642\u4e2d\u304b\u9577\u671f\u30d5\u30a9\u30ed\u30fc\u30a2\u30c3\u30d7\u4e2d\u3067\u3057\u305f\u3002\u5b89\u5168\u6027\u306f\u30d9\u30cd\u30c8\u30af\u30e9\u30c3\u30af\u30b9\u3068\u30a2\u30b6\u30b7\u30c1\u30b8\u30f3\u306b\u901a\u5e38\u671f\u5f85\u3055\u308c\u308b\u3082\u306e\u3068\u540c\u3058\u3067\u3057\u305f\u3002\u30b8\u30d5\u30c8\u30e1\u30cb\u30d6\u306f\u6bd2\u6027\u3092\u9ad8\u3081\u308b\u3053\u3068\u306f\u3042\u308a\u307e\u305b\u3093\u3067\u3057\u305f\u3002\u9aa8\u9ac4\u6291\u5236\u306f\u4f4e\u304f\u4fdd\u305f\u308c\u3001\u9aa8\u9ac4\u6570\u306e\u56de\u5fa9\u6642\u9593\u3082\u307b\u307c\u540c\u3058\u3067\u3057\u305f\u3002\u7ba1\u7406\u53ef\u80fd\u306a\u5206\u5316\u75c7\u5019\u7fa4\u3068QTc\u5ef6\u9577\u306e\u5358\u767a\u75c7\u4f8b\u304c\u3042\u308a\u307e\u3057\u305f\u304c\u3001\u6cbb\u7642\u4e2d\u6b62\u306b\u306f\u81f3\u308a\u307e\u305b\u3093\u3067\u3057\u305f\u3002.<\/p>\n

\u518d\u767a\u307e\u305f\u306f\u96e3\u6cbb\u6027\u3067\u3082\u540c\u3058\u3088\u3046\u306a\u30d1\u30bf\u30fc\u30f3\u304c\u898b\u3089\u308c\u307e\u3057\u305f\u3002R R NPM1\u5909\u7570AML\u3067\u306f\u3001\u5168\u594f\u52b9\u7387\u306f65\u30d1\u30fc\u30bb\u30f3\u30c8\u306b\u9054\u3057\u3001CRc\u306f48\u30d1\u30fc\u30bb\u30f3\u30c8\u306b\u9054\u3057\u307e\u3057\u305f\u3002\u30d9\u30cd\u30c8\u30af\u30e9\u30c3\u30af\u30b9\u672a\u6295\u4e0e\u306e\u60a3\u8005\u3067\u306f\u3001\u5168\u594f\u52b9\u738783\u30d1\u30fc\u30bb\u30f3\u30c8\u3001CRc70\u30d1\u30fc\u30bb\u30f3\u30c8\u3068\u3055\u3089\u306b\u826f\u597d\u306a\u53cd\u5fdc\u3067\u3057\u305f\u3002\u5168\u751f\u5b58\u671f\u9593\u4e2d\u592e\u5024\u306f55\u9031\u9593\u5f31\u3067\u3057\u305f\u3002\u4f55\u4eba\u304b\u306e\u60a3\u8005\u306f\u79fb\u690d\u306b\u79fb\u884c\u3057\u3001\u4f55\u4eba\u304b\u306e\u60a3\u8005\u306f\u30b8\u30d5\u30c8\u30e1\u30cb\u30d6\u7dad\u6301\u7642\u6cd5\u3092\u7d99\u7d9a\u3057\u307e\u3057\u305f\u3002.<\/p>\n

\u3053\u3061\u3089\u3082\u304a\u8aad\u307f\u304f\u3060\u3055\u3044\uff1a \u660e\u6cbb\u88fd\u83d3\u3001\u30ea\u30ea\u30c3\u30af\u30d0\u30a4\u30aa\u306e\u30a4\u30b0\u88fd\u9020\u3092\u652f\u63f4<\/a><\/h4>\n

R R KMT2A\u518d\u914d\u5217\u578bAML\u306b\u5bfe\u3057\u3066\u306f\u3001\u3053\u306e\u30b3\u30f3\u30dc\u306f\u4f9d\u7136\u3068\u3057\u3066\u610f\u5473\u306e\u3042\u308b\u6d3b\u6027\u3092\u793a\u3057\u307e\u3057\u305f\u3002ORR\u306f41\uff05\u3001CRc\u306f28\uff05\u3067\u3057\u305f\u3002\u30d9\u30cd\u30c8\u30af\u30e9\u30af\u30b9\u672a\u6295\u4e0e\u306e\u60a3\u8005\u3067\u3082\u3001ORR70\uff05\u3001CRc60\uff05\u3068\u518d\u3073\u6d3b\u6027\u304c\u56de\u5fa9\u3057\u307e\u3057\u305f\u3002\u5168\u751f\u5b58\u671f\u9593\u4e2d\u592e\u5024\u306f21\u9031\u9593\u5f37\u3067\u3057\u305f\u3002\u3053\u306e\u3046\u30612\u4f8b\u306f\u79fb\u690d\u306b\u9032\u307f\u3001\u305d\u306e\u5f8c\u7dad\u6301\u7642\u6cd5\u3092\u53d7\u3051\u307e\u3057\u305f\u3002\u30b8\u30d5\u30c8\u30e1\u30cb\u30d6\u306b\u95a2\u9023\u3059\u308b\u65b0\u305f\u306a\u554f\u984c\u306f\u306a\u304f\u3001\u5b89\u5168\u6027\u306f\u518d\u3073\u5b89\u5b9a\u3057\u307e\u3057\u305f\u30021\u4f8b\u306e\u9451\u5225\u75c7\u5019\u7fa4\u306f\u30d7\u30ed\u30c8\u30b3\u30fc\u30eb\u6307\u793a\u306b\u3088\u308b\u6cbb\u7642\u3067\u89e3\u6c7a\u3057\u3001\u6cbb\u7642\u304c\u518d\u958b\u3055\u308c\u307e\u3057\u305f\u3002.<\/p>\n

Kura\u793e\u306eCMO\u3067\u3042\u308bMollie Leoni\u6c0f\u306f\u3001\u5b89\u5168\u6027\u3068\u53cd\u5fdc\u306e\u6df1\u3055\u304c\u4e21\u7fa4\u3067\u4e00\u8cab\u3057\u3066\u3044\u308b\u3053\u3068\u3092\u5f37\u8abf\u3057\u307e\u3057\u305f\u3002\u540c\u793e\u306f\u5f15\u304d\u7d9a\u304d\u3001\u30d5\u30ed\u30f3\u30c8\u30e9\u30a4\u30f3\u3068\u518d\u767a\u30fb\u96e3\u6cbb\u6027AML\u306e\u4e21\u65b9\u3092\u5bfe\u8c61\u3068\u3057\u305f\u91cd\u8981\u306aKOMET 017\u8a66\u9a13\u3092\u9032\u3081\u3066\u3044\u304d\u307e\u3059\u3002.<\/p>\n

\u8535<\/a> \u306f\u672c\u65e5\u5348\u5f8c12\u664230\u5206\uff08\u7c73\u56fd\u6771\u90e8\u6642\u9593\uff09\u3088\u308a\u3001\u540c\u793e\u306e\u30ea\u30fc\u30c0\u30fc\u30b7\u30c3\u30d7\u3068\u81e8\u5e8a\u5c02\u9580\u5bb6\u306b\u3088\u308b\u30d0\u30fc\u30c1\u30e3\u30eb\u6295\u8cc7\u5bb6\u30a4\u30d9\u30f3\u30c8\u3092\u958b\u50ac\u3057\u307e\u3059\u3002ASH\u3067\u306e\u8b1b\u6f14\u306e\u30b9\u30e9\u30a4\u30c9\u306f\u5f53\u793e\u30a6\u30a7\u30d6\u30b5\u30a4\u30c8\u3067\u3054\u89a7\u3044\u305f\u3060\u3051\u307e\u3059\u3002.<\/p>","protected":false},"excerpt":{"rendered":"

Kura Oncology and Kyowa Kirin rolled out fresh data on KOMZIFTI ziftomenib paired with venetoclax and azacitidine. The numbers land well for both newly diagnosed and relapsed or refractory AML with NPM1 mutations or KMT2A rearrangements. The readout comes from the ongoing KOMET 007 Phase 1a\/1b study and was presented today at ASH 2025. In newly diagnosed NPM1 mutated AML the triplet came in strong. Among 37 evaluable patients CRc hit 86 percent and complete responses landed at 73 percent. Most striking was that 68 percent of CRc responders cleared molecular MRD by central NGS. Median duration of response and overall survival have not even been reached yet. Two thirds […]<\/p>\n","protected":false},"author":7,"featured_media":25211,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"wprm-recipe-roundup-name":"","wprm-recipe-roundup-description":"","postBodyCss":"","postBodyMargin":[],"postBodyPadding":[],"postBodyBackground":{"backgroundType":"classic","gradient":""},"footnotes":""},"categories":[208,89,211,237,182,206],"tags":[9640,3004,574,424,9639],"ppma_author":[572],"class_list":{"0":"post-25191","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-apac","8":"category-health-tech","9":"category-japan","10":"category-news","11":"category-pharma","12":"category-regional","13":"tag-komzifti","14":"tag-kura-oncology","15":"tag-kyowa-kirin","16":"tag-pharma","17":"tag-venetoclax"},"yoast_head":"\nKura, Kyowa Kirin Show Strong KOMZIFTI AML Results<\/title>\n<meta name=\"description\" content=\"Kura Oncology and Kyowa Kirin report promising KOMZIFTI AML results from the Phase 1a\/1b KOMET 007 study, benefiting patient groups.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/kura-and-kyowa-report-strong-komzifti-aml-data\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kura, Kyowa Kirin Show Strong KOMZIFTI AML Results\" \/>\n<meta property=\"og:description\" content=\"Kura Oncology and Kyowa Kirin report promising KOMZIFTI AML results from the Phase 1a\/1b KOMET 007 study, benefiting patient groups.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/kura-and-kyowa-report-strong-komzifti-aml-data\/\" \/>\n<meta property=\"og:site_name\" content=\"itbusinesstoday\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-09T12:40:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/12\/Kura-Oncology-and-Kyowa-Kirin-Report-Combination-Data-for-KOMZIFTI\u2122-Ziftomenib-with-Venetoclax-and-Azacitidine-in-Newly-Diagnosed-and-Relapsed-Refractory-AML.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"ITBT StaffWriter\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"ITBT StaffWriter\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u5206\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kura, Kyowa Kirin Show Strong KOMZIFTI AML Results","description":"Kura Oncology and Kyowa Kirin report promising KOMZIFTI AML results from the Phase 1a\/1b KOMET 007 study, benefiting patient groups.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/kura-and-kyowa-report-strong-komzifti-aml-data\/","og_locale":"ja_JP","og_type":"article","og_title":"Kura, Kyowa Kirin Show Strong KOMZIFTI AML Results","og_description":"Kura Oncology and Kyowa Kirin report promising KOMZIFTI AML results from the Phase 1a\/1b KOMET 007 study, benefiting patient groups.","og_url":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/kura-and-kyowa-report-strong-komzifti-aml-data\/","og_site_name":"itbusinesstoday","article_published_time":"2025-12-09T12:40:44+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/12\/Kura-Oncology-and-Kyowa-Kirin-Report-Combination-Data-for-KOMZIFTI\u2122-Ziftomenib-with-Venetoclax-and-Azacitidine-in-Newly-Diagnosed-and-Relapsed-Refractory-AML.webp","type":"image\/webp"}],"author":"ITBT StaffWriter","twitter_card":"summary_large_image","twitter_misc":{"\u57f7\u7b46\u8005":"ITBT StaffWriter","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"2\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/kura-and-kyowa-report-strong-komzifti-aml-data\/#article","isPartOf":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/kura-and-kyowa-report-strong-komzifti-aml-data\/"},"author":{"name":"ITBT StaffWriter","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/94fb575e469aff25a4b938814d050f15"},"headline":"Kura and Kyowa Report Strong KOMZIFTI AML Data","datePublished":"2025-12-09T12:40:44+00:00","mainEntityOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/kura-and-kyowa-report-strong-komzifti-aml-data\/"},"wordCount":386,"publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/kura-and-kyowa-report-strong-komzifti-aml-data\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/12\/Kura-Oncology-and-Kyowa-Kirin-Report-Combination-Data-for-KOMZIFTI\u2122-Ziftomenib-with-Venetoclax-and-Azacitidine-in-Newly-Diagnosed-and-Relapsed-Refractory-AML.webp","keywords":["KOMZIFTI","Kura Oncology","Kyowa Kirin","Pharma","venetoclax"],"articleSection":["APAC","Health Tech","Japan","News","Pharma","Regional"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/kura-and-kyowa-report-strong-komzifti-aml-data\/","url":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/kura-and-kyowa-report-strong-komzifti-aml-data\/","name":"Kura, Kyowa Kirin Show Strong KOMZIFTI AML Results","isPartOf":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website"},"primaryImageOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/kura-and-kyowa-report-strong-komzifti-aml-data\/#primaryimage"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/kura-and-kyowa-report-strong-komzifti-aml-data\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/12\/Kura-Oncology-and-Kyowa-Kirin-Report-Combination-Data-for-KOMZIFTI\u2122-Ziftomenib-with-Venetoclax-and-Azacitidine-in-Newly-Diagnosed-and-Relapsed-Refractory-AML.webp","datePublished":"2025-12-09T12:40:44+00:00","description":"Kura Oncology and Kyowa Kirin report promising KOMZIFTI AML results from the Phase 1a\/1b KOMET 007 study, benefiting patient groups.","breadcrumb":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/kura-and-kyowa-report-strong-komzifti-aml-data\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/itbusinesstoday.com\/health-tech\/pharma\/kura-and-kyowa-report-strong-komzifti-aml-data\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/kura-and-kyowa-report-strong-komzifti-aml-data\/#primaryimage","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/12\/Kura-Oncology-and-Kyowa-Kirin-Report-Combination-Data-for-KOMZIFTI\u2122-Ziftomenib-with-Venetoclax-and-Azacitidine-in-Newly-Diagnosed-and-Relapsed-Refractory-AML.webp","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/12\/Kura-Oncology-and-Kyowa-Kirin-Report-Combination-Data-for-KOMZIFTI\u2122-Ziftomenib-with-Venetoclax-and-Azacitidine-in-Newly-Diagnosed-and-Relapsed-Refractory-AML.webp","width":1200,"height":800,"caption":"Kura Oncology"},{"@type":"BreadcrumbList","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/kura-and-kyowa-report-strong-komzifti-aml-data\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/itbusinesstoday.com\/"},{"@type":"ListItem","position":2,"name":"Kura and Kyowa Report Strong KOMZIFTI AML Data"}]},{"@type":"WebSite","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","description":"","publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","width":663,"height":275,"caption":"itbusinesstoday"},"image":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/94fb575e469aff25a4b938814d050f15","name":"ITBT\u30b9\u30bf\u30c3\u30d5\u30e9\u30a4\u30bf\u30fc","image":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png90b3cb23d1d9c08733d969d29ea2d30d","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png","caption":"ITBT StaffWriter"},"description":"ITBT\u30b9\u30bf\u30c3\u30d5\u30e9\u30a4\u30bf\u30fc\u306f\u3001IT Business Today\u306e\u793e\u5185\u5bc4\u7a3f\u8005\u3067\u3001\u30bf\u30a4\u30e0\u30ea\u30fc\u306a\u30cb\u30e5\u30fc\u30b9\u3068QuickBytes\u306e\u914d\u4fe1\u3092\u62c5\u5f53\u3057\u3066\u3044\u307e\u3059\u3002IT\u3001\u30cf\u30a4\u30c6\u30af\u3001\u4f01\u696d\u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3\u306e\u6700\u65b0\u52d5\u5411\u3092\u30ab\u30d0\u30fc\u3057\u3001\u7c21\u6f54\u3067\u30a4\u30f3\u30d1\u30af\u30c8\u306e\u3042\u308b\u6700\u65b0\u60c5\u5831\u3092\u8aad\u8005\u306b\u63d0\u4f9b\u3057\u3066\u3044\u307e\u3059\u3002","sameAs":["https:\/\/itbusinesstoday.com\/"],"url":"https:\/\/itbusinesstoday.com\/ja\/author\/itbt-staffwriter\/"}]}},"authors":[{"term_id":572,"user_id":7,"is_guest":0,"slug":"itbt-staffwriter","display_name":"ITBT StaffWriter","avatar_url":{"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png","url2x":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png"},"0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""}],"_links":{"self":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/25191","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/comments?post=25191"}],"version-history":[{"count":1,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/25191\/revisions"}],"predecessor-version":[{"id":25192,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/25191\/revisions\/25192"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media\/25211"}],"wp:attachment":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media?parent=25191"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/categories?post=25191"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/tags?post=25191"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/ppma_author?post=25191"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}